ArticleReproductive sciences (Thousand Oaks, Calif.)2025
CHAF1A Promotes Preadipocyte Differentiation and Contributes to Macrosomia in Gestational Diabetes Mellitus.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gestational diabetes mellitus (GDM) leads to macrosomia primarily due to fat accumulation caused by adipocyte differentiation. This study aims to investigate the role and underlying mechanisms of Chromatin assembly factor 1 subunit A (CHAF1A) in GDM-induced macrosomia. CHAF1A expression was compared between the GDM with macrosomia group (n = 25) and the normal glucose with normal weight group (n = 15), and the correlation between CHAF1A and neonatal body composition was examined. CHAF1A was overexpressed and knocked down in human visceral preadipocytes (HPA-v), and the effects on cell proliferation and adipogenic differentiation were measured, then the expressions of adipogenic markers were determined. Transcriptome sequencing was employed to investigate the potential mechanisms. Placental immunohistochemistry showed that the expression of CHAF1A in the GDM with macrosomia group was significantly higher than that in the control group (P < 0.05). Correlation analysis showed that CHAF1A expression was positively correlated with neonatal weight, body fat percentage, and fat mass. In functional assays, preadipocytes overexpressing CHAF1A showed enhanced proliferation and adipogenic differentiation, while knockdown of CHAF1A resulted in the opposite effect. Moreover, CHAF1A affected the expression of adipogenic markers. Transcriptome sequencing analysis showed that the differentially expressed genes after CHAF1A silencing were enriched in signaling pathways closely related to preadipocyte differentiation and hormone secretion and synthesis, such as JAK-STAT, Wnt and BMP signaling pathways. CHAF1A promotes the proliferation and differentiation of preadipocytes, which may be a direction for exploring fetal fat accumulation leading to macrosomia in GDM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.